Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.

Bobrov E, Skobeleva N, Restifo D, Beglyarova N, Cai KQ, Handorf E, Campbell K, Proia DA, Khazak V, Golemis EA, Astsaturov I.

Oncotarget. 2017 Jan 17;8(3):4399-4409. doi: 10.18632/oncotarget.12642.

2.

Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.

Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I.

Clin Cancer Res. 2016 Dec 15;22(24):6153-6163. Epub 2016 Jul 6.

Supplemental Content

Loading ...
Support Center